KALDOR,NICHOLAS AND THE REAL-WORLD - TURNER,MS

被引：0
|
作者：
PRESSMAN, S
机构：
来源：
REVIEW OF SOCIAL ECONOMY | 1995年 / 53卷 / 01期
关键词：
D O I：
10.1080/00346769500000011
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：160 / 163
页数：4
相关论文
共 50 条
  • [21] Real-world study: from real-world data to real-world evidence
    Wen, Yi
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [22] Nicholas Kaldor after thirty years
    King, John Edward
    PSL QUARTERLY REVIEW, 2016, 69 (277) : 107 - 133
  • [23] KALDOR,NICHOLAS (1908-1986)
    URQUIDI, VL
    TRIMESTRE ECONOMICO, 1987, 54 (216): : 919 - 925
  • [24] Real-World Battles with Real-World Data
    Brown, Jeffrey
    Bate, Andrew
    Platt, Robert
    Raebel, Marsha
    Sauer, Brian
    Trifiro, Gianluca
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 254 - 255
  • [25] Real-world experience of ocrelizumab initiation in a diverse ms population
    Coban, H.
    Germaine, S.
    Dimaandal, I.
    Haberli, N.
    Padam, C.
    Creed, M.
    Imitola, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 548 - 549
  • [26] Ocrelizumab and hypogammaglobulinemia: a real-world retrospective MS cohort study
    Nobile, S.
    Beauchemin, P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 324 - 324
  • [27] Real-world validation of the 2017 McDonald criteria for pediatric MS
    Wong, Yu Yi M.
    de Mol, C. Louk
    de Vries, Roos M. van der Vuurst
    van Pelt, E. Danielle
    Ketelslegers, Immy A.
    Catsman-Berrevoets, Coriene E.
    Neuteboom, Rinze F.
    Hintzen, Rogier Q.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (02):
  • [28] Real-world validation of the 2017 McDonald criteria for pediatric MS
    不详
    NEUROLOGY, 2019, 93 (04) : 157 - 157
  • [29] Real-world data on relapse-independent worsening in MS
    Bardo, Maximilian
    Frahm, Niklas
    Peters, Melanie
    Ellenberger, David
    Stahmann, Alexander
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 449 - 449
  • [30] Real-world trials to answer real-world questions
    Freemantle, N
    Blonde, L
    Bolinder, B
    Gerber, RA
    Hobbs, FDR
    Martinez, L
    Ross, S
    PHARMACOECONOMICS, 2005, 23 (08) : 747 - 754
12345